Safety and Efficacy Study of rAAV.sFlt-1 in Patients With Exudative Age-Related Macular Degeneration

NCT01494805 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Macular Degeneration
Age-related Maculopathies
Age-related Maculopathy
Maculopathies,Age-related
Maculopathy,Age-related
Retinal Degeneration
Retinal Neovascularization
Eye Diseases

Interventions

BIOLOGICAL: rAAV.sFlt-1
BIOLOGICAL: rAAV.sFlt-1
OTHER: Control (ranibizumab alone)

Sponsor

Lions Eye Institute, Perth, Western Australia

Collaborators

[object Object]